Stay updated with breaking news from Column Group. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Gross proceeds expected to include $60 million from a committed PIPE and up to $175 million held in trust Anticipated cash resources will fund eFFECTOR's ...
Appia Bio Launches With $52 Million Series A Financing and Establishes Scientific Advisory Board Proceeds will be used to progress stem cell derived CAR-engineered invariant natural killer T cells (CAR-iNKT) to the clinic in hematological and solid tumor indications News provided by Share this article Share this article LOS ANGELES, May 11, 2021 /PRNewswire/ -- Appia Bio, Inc., an early stage biotechnology company developing engineered allogeneic cell therapies from hematopoietic stem cells (HSCs) for cancer patients, today announced its launch from stealth backed by $52 million Series A fina...
Eikon Therapeutics closes $148M financing to develop super-resolution microscopy 06 May 2021 California-based firm to integrate advanced optics, machine learning with biochemistry; its target application is drug discovery. Eikon focuses on live-cell super-resolution microscopy for drug discovery.Eikon Therapeutics, a Hayward, California-based company focused on live-cell super-resolution microscopy and engineering for drug discovery, has this week announced that it has closed a $148 million Series A financing round. The funding is led by The Column Group with participation from Foresite Cap...
Stealthy Eikon unveils $148M in funding and ex-Merck exec Perlmutter at helm Eikon Therapeutics joins a growing number of startups researching how proteins move in cells as a basis for drug discovery. Roger Perlmutter joins Eikon as its CEO just four months after he retired as Merck’s top research executive. Shares0 Eikon Therapeutics, a new biotech startup that uses advanced techniques for visualizing proteins and combines that capability with computational approaches to drug screening , has emerged from stealth with $148 million in funding and a veteran Merck executive at the helm. Th...
RTW Leads $106 Million Financing Round in Tenaya Therapeutics RTW Venture Fund Limited (the "Company"), the London Stock Exchange-listed investment company focused on identifying transformative assets with high growth potential across the life sciences sector, is pleased to note the announcement by Tenaya Therapeutics, Inc. ("Tenaya") on 01 March 2021 of its completion of a $106 million Series C financing round led by RTW Investments, LP (the "Investment Manager"). The Company, alongside other investment vehicles of the Investment Manager, confirms that it participated in the financing round...